US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

690.06

-10.2920-1.47%

Number of Gainers:31

Number of Losers:111

Number of Flat:12

PE:- -

High:700.46

Open:700.46

Low:688.41

Close:700.46

Volume:26.86M

Turnover:810.41M

Market Cap:482.47B

Float Cap:366.93B

Loading ...

TransCode Says Preclinical Study Shows Survival Benefit for TTX-MC138 in Breast Cancer Bone Metastasis Model

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live

Mobix Labs, - Announces Definitive Agreement to Buy Vision Aerial

THOMSON REUTERS

Mobix Labs - Vision Aerial Acquisition Expected to Close in Q4 2026, Subject to Conditions

THOMSON REUTERS

Press Release: Mobix Labs' Pending Drone Acquisition, Vision Aerial, Projects 93% Revenue Growth

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Kazia Therapeutics Unveils New Investor-Focused Website

Clear Secure Partners with CrowdStrike to Integrate Clear1 Identity Verification into Falcon Platform

Stevanato Group (STVN) Receives a Hold from Morgan Stanley

Zhihu Details July–August 2026 Share Buybacks and Governance Updates in Form 6-K

Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program

Macquarie Upgrades Chagee to Outperform From Neutral, $10.20 Price Target

MT Newswires Live

Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Waterdrop Founder Shen Peng Appointed Vice Chairman of HKU Business School North China Alumni Association

Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market

Humana Stock And 2 Healthcare Names Backing The Shift To Preventive Care

Simply Wall St.

Nexalis Therapeutics Posts Wider Half-Year Loss and Negative Asset Backing

Chagee Holdings (CHA) After Results Buyback And Board Change Looks Undervalued

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BK4539/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":690.16516,"timestamp":1788184115342,"preClose":700.45715,"halted":0,"volume":26872261,"delay":0,"changeRate":-0.014693,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-10.291992,"latestTime":"08-31 09:48:35 EDT","open":700.4583,"high":700.4583,"low":688.4115,"amount":810407690.882585,"amplitude":0.017199,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.533593,"peRate":151.680589,"turnoverRate":0.002066,"increases":32,"decrements":113,"flats":6,"marketCap":482471705492.75,"floatMarketCap":366933283652.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":700.4583,"amplitude":0.017199,"preClose":700.45715,"low":688.4115,"pbRate":"5.533593","latestPrice":690.0642,"volume":26864038,"delay":0,"open":700.4583,"prevYearClose":881.5255,"prevWeekClose":700.4571,"prevMonthClose":673.0273,"prevQuarterClose":742.922,"fiveDayClose":685.7458,"twentyDayClose":689.4023,"sixtyDayClose":734.3536,"secType":"PLATE","market":"US","turnoverRate":0.002064,"peRate":151.680589,"marketCap":482399763018.75,"floatMarketCap":366864667554.25,"timestamp":1788184114095,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":31,"down":111,"flat":12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663008171","title":"TransCode Says Preclinical Study Shows Survival Benefit for TTX-MC138 in Breast Cancer Bone Metastasis Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008171","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008171?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:07","pubTimestamp":1788178055,"startTime":"0","endTime":"0","summary":"TransCode says preclinical study shows survival benefit for TTX-MC138 in breast cancer bone metastasis modelTransCode Therapeutics disclosed peer-reviewed preclinical data showing its lead candidate T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL7NnQJj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008151","title":"Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008151","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008151?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:04","pubTimestamp":1788177853,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-202.The trial is studying the drug for the treatment of dry eye disease in China, according to a Monday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1574","LENZ","01477","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663700860","title":"Mobix Labs, - Announces Definitive Agreement to Buy Vision Aerial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663700860?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177773,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S06T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4141","MOBX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663200896","title":"Mobix Labs - Vision Aerial Acquisition Expected to Close in Q4 2026, Subject to Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2663200896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663200896?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177773,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S06T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","MOBX","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663085520","title":"Press Release: Mobix Labs' Pending Drone Acquisition, Vision Aerial, Projects 93% Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2663085520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663085520?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"-- 46% projected revenue growth in 2026; 93% in 2027 ---- U.S. Navy and L3Harris among Vision Aerial customers --IRVINE, Calif. & BOZEMAN, Mont.--(BUSINESS WIRE)--August 31, 2026--Mobix Labs, Inc. (Na","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MOBX","BK4141","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008480","title":"Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008480?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353254/0/en/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-meeting-for-phase-3-registration-study-of-cad-1005-in-heparin-induced-thrombocytopenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LABU","LENZ","BK4134","BK4007","BK4613","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4539","HIT","BK4173","BK4023","KD","IE0031619046.USD","SAP","IE00B7SZL793.SGD","BK4139","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008468","title":"Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008468","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008468?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Aug.  31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353265/0/en/chemomab-therapeutics-to-present-at-h-c-wainwright-28th-annual-global-investor-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600856","title":"Kazia Therapeutics Unveils New Investor-Focused Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600856?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:57","pubTimestamp":1788177432,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics ( ($KZIA) ) has shared an announcement. On August 28, 2026, Kazia Therapeutics launched a new corporate website at www.kaziatx.c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-unveils-new-investor-focused-website?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-unveils-new-investor-focused-website?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663842008","title":"Clear Secure Partners with CrowdStrike to Integrate Clear1 Identity Verification into Falcon Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2663842008","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663842008?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:55","pubTimestamp":1788177344,"startTime":"0","endTime":"0","summary":"Clear Secure partners with CrowdStrike to integrate CLEAR1 identity verification into Falcon platformCLEAR entered a strategic partnership with CrowdStrike to integrate CLEAR1 verified identity into t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL27ZKbZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU1804176565.USD","CRWD","LU2106854487.HKD","AIPI","LU1951198990.SGD","IE00BZ9MQY76.HKD","PSWD","BK4097","CLOD","LU1548497426.USD","SPAM","BK4539","LU0081259029.USD","LU1923623000.USD","LU1923622614.USD","BK4585","LU2125909916.SGD","YOU","LU1064131342.USD","IE00B19Z9P08.USD","LU1917777945.USD","BK4588","CRWC","CIBR","LU0266013472.USD","LU1992135472.HKD","LU2272731782.SGD","LU2211815571.USD","LU2125909247.SGD","LU1720051017.SGD","LU2023250504.SGD","LU2265009873.SGD","LU1992135399.USD","LU2264538146.SGD","BUG","BK4560","HAKY","BK4551","LU1720051108.HKD","IE00B19Z9Z06.USD","IGV","BK4598","LU1951200564.SGD","BK4532","LU0719512351.SGD","IE00B894F039.SGD","CRWL","WCBR","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663500859","title":"Stevanato Group (STVN) Receives a Hold from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2663500859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663500859?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:55","pubTimestamp":1788177339,"startTime":"0","endTime":"0","summary":"In a report released today, Kallum Titchmarsh from Morgan Stanley maintained a Hold rating on Stevanato Group, with a price target of $20.00. Titch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stevanato-group-stvn-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stevanato-group-stvn-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["STVN","BK4121","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077728","title":"Zhihu Details July–August 2026 Share Buybacks and Governance Updates in Form 6-K","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077728","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077728?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:19","pubTimestamp":1788175189,"startTime":"0","endTime":"0","summary":"The latest update is out from Zhihu ( ($ZH) ). Zhihu filed a Form 6-K for August 2026 detailing several Hong Kong Next Day Disclosure Returns cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zhihu-details-july-august-2026-share-buybacks-and-governance-updates-in-form-6-k?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zhihu-details-july-august-2026-share-buybacks-and-governance-updates-in-form-6-k?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4509","HK0000252160.HKD","BK4539","ZH","BK4077","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077779","title":"Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077779","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077779?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:19","pubTimestamp":1788175180,"startTime":"0","endTime":"0","summary":"An announcement from Kazia Therapeutics ( ($KZIA) ) is now available. On August 28, 2026, Kazia Therapeutics entered an underwriting agreement for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-secures-40-million-u-s-offering-to-accelerate-paxalisib-oncology-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-secures-40-million-u-s-offering-to-accelerate-paxalisib-oncology-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","AAQC","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663958077","title":"Macquarie Upgrades Chagee to Outperform From Neutral, $10.20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2663958077","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663958077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:09","pubTimestamp":1788174561,"startTime":"0","endTime":"0","summary":"Chagee (CHA) has an average rating of overweight and mean price target of $15.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHA","LU0348766576.USD","LU0348767384.USD","BK4526","BK4610","BK4539","BK4209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077385","title":"Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077385","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077385?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:03","pubTimestamp":1788174204,"startTime":"0","endTime":"0","summary":"Alzamend Neuro director Milton C. Ault III sells 2,000 shares worth $3,116.20Director Milton C. Ault III sold 2,000 Alzamend Neuro common shares on Aug. 26, 2026.Sale priced at USD 1.56 per share; dir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5VZc2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ALZN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663318077","title":"Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2663318077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663318077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:00","pubTimestamp":1788174000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353154/0/en/beam-therapeutics-to-participate-in-upcoming-september-2026-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192275043","title":"Waterdrop Founder Shen Peng Appointed Vice Chairman of HKU Business School North China Alumni Association","url":"https://stock-news.laohu8.com/highlight/detail?id=1192275043","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192275043?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:12","pubTimestamp":1788171153,"startTime":"0","endTime":"0","summary":"On August 30, Waterdrop Inc. (NYSE: WDH) founder and CEO Shen Peng was appointed as Vice Chairman of the Hong Kong University (HKU) Business School's North China Alumni Association, with a term...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4509","BK4539","BK4173","WDH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071481","title":"Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663071481?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:50","pubTimestamp":1788169824,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics ( ($HK:2487) ) just unveiled an announcement. Cutia Therapeutics reported solid progress in its interim business update for the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-accelerates-commercial-push-in-chinas-dermatology-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-accelerates-commercial-push-in-chinas-dermatology-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077852","title":"Humana Stock And 2 Healthcare Names Backing The Shift To Preventive Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077852?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:25","pubTimestamp":1788168318,"startTime":"0","endTime":"0","summary":"Investors are watching a cultural pivot as more people question hyper quantified wellness and look for care that treats the whole person instead of just the data points. That shift could reshape where money flows across healthcare and wellness. Miss it and you could overlook companies that fit this mood. This article breaks down three stocks from our Holistic and Preventive Healthcare & Wellness Providers screener that appear closely tied to this news story.\nThe stocks highlighted below are a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-stock-and-2-healthcare-names-backing-the-shift-to-pre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-stock-and-2-healthcare-names-backing-the-shift-to-pre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HCSG","BK4154","LU1093756325.SGD","LU0390134368.USD","LU0128526141.USD","BK4581","SG9999014021.USD","BK4539","LU0029874061.USD","LU0070302665.USD","BK4137","BK4585","XLV","SG9999014013.SGD","BK4533","BK4566","LU0211331839.USD","BK7093","BK4588","LU0320765489.SGD","LU1093756168.USD","LU0170899867.USD","LU0266013472.USD","PRVA","LU0256863811.USD","LU0348723411.USD","LU0208291251.USD","BK7500","HUM.AU","FXH","LU0417517546.SGD","LABU","IHF","XBI","SG9999014005.SGD","HUM","LU0238689110.USD","BK6088","Z4D.SI","BK6046","BK4196","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079604","title":"Nexalis Therapeutics Posts Wider Half-Year Loss and Negative Asset Backing","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079604?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:24","pubTimestamp":1788168297,"startTime":"0","endTime":"0","summary":"InhaleRx Limited ( ($AU:NX1) ) just unveiled an update. Nexalis Therapeutics Ltd reported a half-year loss after tax of $1.30 million for the perio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-posts-wider-half-year-loss-and-negative-asset-backing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-posts-wider-half-year-loss-and-negative-asset-backing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663109077","title":"Chagee Holdings (CHA) After Results Buyback And Board Change Looks Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2663109077","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663109077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:23","pubTimestamp":1788168227,"startTime":"0","endTime":"0","summary":"Chagee Holdings (NasdaqGS:CHA) has drawn fresh attention after reporting second quarter 2026 results, confirming a completed share buyback, and announcing a board resignation. These developments give investors several new data points to assess the stock.\nThe latest Q2 results, completed buyback and board change arrive against a weaker share price backdrop for Chagee Holdings, with the stock at $10.8 after a 1-day share price return of 4.35%. However, the year-to-date share price return is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/4214000-choice2-main-header/1585186565403","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4214000-choice2-main-header/1585186565403"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-services/nasdaq-cha/chagee-holdings/news/chagee-holdings-cha-after-results-buyback-and-board-change-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-services/nasdaq-cha/chagee-holdings/news/chagee-holdings-cha-after-results-buyback-and-board-change-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","BK4526","CHA","BK4539","BK4209","LU0348766576.USD","BK4610"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":40,"pageCount":1,"totalSize":789,"code":"91000000","status":"200"}]}}